Ampyra and Cirrhosis alcoholic - a phase IV clinical study of FDA data


Cirrhosis alcoholic is reported only by a few people who take Ampyra.

The phase IV clinical study analyzes which people take Ampyra and have Cirrhosis alcoholic. It is created by eHealthMe based on reports of 72,990 people who have side effects while taking Ampyra from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 25, 2022

72,990 people reported to have side effects when taking Ampyra.
Among them, 3 people (0.0%) have Cirrhosis alcoholic.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 73,128 Ampyra users for its effectiveness, alternative drugs and more.

What is Cirrhosis alcoholic?

Cirrhosis alcoholic (chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue caused by alcoholism) is found to be associated with 358 drugs and 156 conditions by eHealthMe.

Number of Ampyra and Cirrhosis alcoholic reports submitted per year:

Could Ampyra cause Cirrhosis alcoholic?

Gender of people who have Cirrhosis alcoholic when taking Ampyra *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Cirrhosis alcoholic when taking Ampyra *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Common drugs people take besides Ampyra *:

  1. Vitamin D: 2 people, 66.67%
  2. Lasix: 2 people, 66.67%
  3. Gablofen: 2 people, 66.67%
  4. Tramadol: 2 people, 66.67%
  5. Tecfidera: 2 people, 66.67%
  6. Spiriva: 2 people, 66.67%
  7. Ranitidine: 2 people, 66.67%
  8. Klor-Con: 2 people, 66.67%
  9. Vitamin B1: 2 people, 66.67%
  10. Lioresal: 2 people, 66.67%

Common side effects people have besides Cirrhosis alcoholic *:

  1. Death: 3 people, 100.00%
  2. Urinary Incontinence (inability to control the flow of urine and involuntary urination): 2 people, 66.67%
  3. Weakness: 1 person, 33.33%
  4. General Physical Health Deterioration (weak health status): 1 person, 33.33%
  5. Gait Disturbance: 1 person, 33.33%
  6. Fall: 1 person, 33.33%
  7. Fainting (loss of consciousness and postural tone): 1 person, 33.33%
  8. Failure To Thrive (inadequate weight gain and physical growth in children): 1 person, 33.33%
  9. Faecal Incontinence (a lack of control over passing stool): 1 person, 33.33%
  10. Eyes - Bulging (swelling of eyes): 1 person, 33.33%

Common conditions people have *:

  1. Neuropathy Peripheral (surface nerve damage): 1 person, 33.33%
  2. Gastritis (inflammation of stomach): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ampyra and have Cirrhosis alcoholic?

Check whether Cirrhosis alcoholic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Ampyra:

Cirrhosis alcoholic treatments and more:

COVID vaccines that are related to Cirrhosis alcoholic:

How severe was Cirrhosis alcoholic and when was it recovered:

Expand to all the drugs that have ingredients of dalfampridine:

All the drugs that are associated with Cirrhosis alcoholic:

All the conditions that are associated with Cirrhosis alcoholic:

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: